Restricted accessReview articleFirst published online 2026-1
Immune and Virological Factors Influencing Human Respiratory Syncytial Virus Circulation and Increased Prevalence During and After the COVID-19 Pandemic
Human respiratory syncytial virus (hRSV) is a leading cause of respiratory infections in infants and older adults. The COVID-19 pandemic disrupted hRSV transmission due to non-pharmaceutical interventions (NPI), resulting in atypical circulation patterns, earlier seasonal peaks, and increased post-pandemic prevalence. Two key factors are proposed to underlie these changes: a reduced specific immune response due to decreased viral exposure and the emergence of novel hRSV variants. These factors contributed to a larger cohort of immunologically naïve children and lower levels of maternally derived antibodies, increasing susceptibility to severe hRSV disease, particularly in infants and children. Additionally, adults experienced waning immunity following prolonged periods of limited hRSV circulation. The post-pandemic resurgence was accompanied by the emergence of novel hRSV variants with altered transmissibility and virulence, such as GB5.0.6a in Europe and B.D.E.1 in China. These variants may reflect mutations driven by the reduced immunity, though further research is needed to assess their pathogenicity. Understanding the interplay between the reduced immunity due to NPI and virological factors is essential for addressing hRSV epidemiology. Enhanced molecular surveillance and immunological monitoring are crucial for guiding vaccination strategies and protecting vulnerable populations against future hRSV outbreaks.
AeffnerF, TraylorZP, YuENZ, et al.Double-stranded RNA induces similar pulmonary dysfunction to respiratory syncytial virus in BALB/c mice. Am J Physiol Lung Cell Mol Physiol, 2011; 301(1):L99–L109.
2.
AgiusG, DindinaudG, BiggarRJ, et al.An epidemic of respiratory syncytial virus in elderly people: Clinical and serological findings. J Med Virol, 1990; 30(2):117–127.
3.
AttaianeseF, GuiducciS, TrapaniS, et al.Reshaping our knowledge: Advancements in understanding the immune response to human respiratory syncytial virus. Pathogens, 2023; 12(9):1118.
4.
BardsleyM, MorbeyRA, HughesHE, et al.Epidemiology of respiratory syncytial virus in children younger than 5 years in England during the COVID-19 pandemic, measured by laboratory, clinical, and syndromic surveillance: A Retrospective Observational Study. Lancet Infect Dis, 2023; 23(1):56–66.
5.
BøåsH, HavdalLB, StørdalK, et al.; Norwegian Enhanced Pediatric Immunisation Surveillance (NorEPIS) Network. No association between disease severity and respiratory syncytial virus subtypes RSV-A and RSV-B in hospitalized young children in Norway. PLoS One, 2024; 19(3):e0298104.
6.
BohmwaldK, EspinozaJ, Rey-JuradoE, et al.Human Respiratory Syncytial Virus: Infection and pathology. Semin Respir Crit Care Med, 2016; 37(4):522–537.
7.
BonninFA, TalaricoLB, FerollaFM, et al.; GUTI Respiratory Infections Network. Antibody levels against respiratory syncytial virus fusion protein conformations and lack of association with life-threatening infection in previously healthy infants. Vaccine, 2024; 42(25):126119.
8.
BuchwaldAG, GrahamBS, TraoreA, et al.Respiratory Syncytial Virus (RSV) neutralizing antibodies at birth predict protection from RSV illness in infants in the first 3 months of life. Clin Infect Dis, 2021; 73(11):e4421–e4427.
9.
BullJJ, KoelleK, AntiaR. Waning immunity drives respiratory virus evolution and reinfection. Evol Med Public Health, 2025; 13(1):101–110.
10.
CaiB, ChenY, AgostiY, et al.A statistical model to predict protection against infant respiratory syncytial virus disease through maternal immunization. Vaccines (Basel), 2024; 12(12):1351.
11.
Cantú-FloresK, Rivera-AlfaroG, Muñoz-EscalanteJC, et al.Global distribution of respiratory syncytial virus A and B infections: A systematic review. Pathog Glob Health, 2022; 116(7):398–409.
12.
CoindyEL, EfstathiouC, TalwarS, et al.; PROMISE investigators. Antibody-mediated protection against respiratory syncytial virus in children. Eur Respir Rev, 2024; 33(174):240106.
13.
CorreaD, GiraldoDM, GallegoS, et al.Immunity towards human Respiratory Syncytial Virus. Acta Virol, 2023; 67:11887.
14.
Da SilvaRP, ThoméBL, Da SouzaAPD. Exploring the immune response against RSV and SARS-CoV-2 infection in children. Biology (Basel), 2023; 12(9):1223.
15.
DeC, PicklesRJ, YaoW, et al.Human T cells efficiently control RSV infection. JCI Insight, 2023; 8(11):e168110.
16.
DebbagR, Ávila-AgüeroML, BreaJ, et al.Confronting the challenge: A regional perspective by the Latin American Pediatric Infectious Diseases Society (SLIPE) Expert Group on Respiratory Syncytial Virus—Tackling the burden of disease and implementing preventive solutions. Front Pediatr, 2024; 12:1386082.
17.
DelgadoMF, CovielloS, MonsalvoAC, et al.Lack of antibody affinity maturation due to poor toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med, 2009; 15(1):34–41.
18.
Den HartogG, Van KasterenPB, ScheppRM, et al.Decline of RSV-specific antibodies during the COVID-19 pandemic. Lancet Infect Dis, 2023; 23(1):23–25.
19.
EddensT, ParksOB, WilliamsJV. Neonatal immune responses to respiratory viruses. Front Immunol, 2022; 13:863149.
20.
EdenJ-S, SikazweC, XieR, et al.; Australian RSV study group. Off-season RSV epidemics in Australia after easing of COVID-19 restrictions. Nat Commun, 2022; 13(1):2884.
21.
EnglundJA. Passive protection against respiratory syncytial virus disease in infants: The role of maternal antibody. Pediatr Infect Dis J, 1994; 13(5):449–453.
22.
EvansD, KunerthH, MummE, et al.Genomic epidemiology of human respiratory syncytial virus, Minnesota, USA, July 2023–February 2024. Emerg Infect Dis, 2024; 30(11):2414–2418.
23.
FalsaperlaR, SortinoV, La CognataD, et al.Acute Respiratory Tract Infections (ARTIs) in children after COVID-19-related social distancing: An epidemiological study in a single Center of Southern Italy. Diagnostics, 2024; 14(13):1341.
24.
FengZ, XuL, XieZ. Receptors for respiratory syncytial virus infection and host factors regulating the life cycle of respiratory syncytial virus. Front Cell Infect Microbiol, 2022; 12:858629.
25.
FodhaI, VabretA, GhediraL, et al.Respiratory syncytial virus infections in hospitalized infants: Association between viral load, virus subgroup, and disease severity. J Med Virol, 2007; 79(12):1951–1958.
26.
FoleyDA, PhuongLK, PeplinskiJ, et al.Examining the interseasonal resurgence of respiratory syncytial virus in Western Australia. Arch Dis Child, 2022; 107(3):e1.2–e7.
27.
FooSY, PhippsS. Regulation of inducible BALT formation and contribution to immunity and pathology. Mucosal Immunol, 2010; 3(6):537–544.
28.
FourgeaudJ, ToubianaJ, ChappuyH, et al.Impact of public health measures on the post-COVID-19 respiratory syncytial virus epidemics in France. Eur J Clin Microbiol Infect Dis, 2021; 40(11):2389–2395.
29.
Galindo-FragaA, Del Carmen Guerra-de-BlasP, Ortiz-HernándezAA, et al.; Mexican Emerging Infectious Disease Clinical Research Network. Prospective cohort study of patient demographics, viral agents, seasonality, and outcomes of influenza-like illness in Mexico in the late H1N1-pandemic and post-pandemic years (2010-2014). IJID Reg, 2024; 12:100394.
30.
GaoX, LiuC, WangS. Mucosal immune responses in the lung during respiratory infection: The organization and regulation of iBALT structure. Hlife, 2023; 1(2):71–82.
31.
GollwitzerES, SaglaniS, TrompetteA, et al.Lung microbiota promotes tolerance to allergens in neonates via PD-L1. Nat Med, 2014; 20(6):642–647; doi: 10.1038/nm.3568
32.
GoyaS, GalianoM, NauwelaersI, et al.Toward unified molecular surveillance of RSV: A proposal for genotype definition. Influenza Resp Viruses, 2020; 14(3):274–285.
33.
GoyaS, RuisC, NeherRA, et al.Standardized phylogenetic classification of human respiratory syncytial virus below the subgroup level. Emerg Infect Dis, 2024; 30(8):1631–1641.
34.
GuoL, YangZ, ZhangL, et al.Systematic review of the effects of environmental factors on virus inactivation: Implications for coronavirus disease 2019. Int J Environ Sci Technol (Tehran), 2021; 18(9):2865–2878.
35.
HallCB, WalshEE, LongCE, et al.Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis, 1991; 163(4):693–698.
36.
HanadaS, PirzadehM, CarverKY, et al.Respiratory viral infection-induced microbiome alterations and secondary bacterial pneumonia. Front Immunol, 2018; 9:2640.
37.
HartmannK, LieseJG, KemmlingD, et al.Clinical burden of respiratory syncytial virus in hospitalized children aged ≤5 years (INSPIRE Study). J Infect Dis, 2022; 226(3):386–395.
38.
HaversFP, WhitakerM, MelgarM, et al.; RSV-NET Surveillance Team. Characteristics and outcomes among adults aged ≥60 years hospitalized with laboratory-confirmed respiratory syncytial virus—RSV-NET, 12 States, July 2022–June 2023. MMWR Morb Mortal Wkly Rep, 2023; 72(40):1075–1082.
39.
HayekH, AmarinJZ, QwaiderYZ, et al.Co-detection of respiratory syncytial virus with other respiratory viruses across all age groups before and during the COVID-19 pandemic. Front Virol, 2023; 3:1156012.
40.
Hernández BautistaPF, Cabrera GaytánDA, Vallejos ParásA, et al.Respiratory virus behavior: Results of laboratory-based epidemiological surveillance. PLoS One, 2024; 19(10):e0307322.
41.
HönemannM, MaierM, FrilleA, et al.Respiratory syncytial virus in adult patients at a tertiary care hospital in germany: Clinical features and molecular epidemiology of the fusion protein in the severe respiratory season of 2022/2023. Viruses, 2024; 16(6):943.
42.
HornslethA, KlugB, NirM, et al.Severity of respiratory syncytial virus disease related to type and genotype of virus and to cytokine values in nasopharyngeal secretions. Pediatr Infect Dis J, 1998; 17(12):1114–1121.
43.
HwangJY, RandallTD, Silva-SanchezA. Inducible bronchus-associated lymphoid tissue: Taming inflammation in the lung. Front Immunol, 2016; 7:258.
44.
JafriHS, WuX, MakariD, et al.Distribution of respiratory syncytial virus subtypes A and B among infants presenting to the emergency department with lower respiratory tract infection or apnea. Pediatr Infect Dis J, 2013; 32(4):335–340.
45.
JiangM-Y, DuanY-P, TongX-L, et al.Clinical manifestations of respiratory syncytial virus infection and the risk of wheezing and recurrent wheezing illness: A systematic review and meta-analysis. World J Pediatr, 2023; 19(11):1030–1040.
46.
JiangW, XuL, WangY, et al.Exploring immunity debt: Dynamic alterations in RSV antibody levels in children under 5 years during the COVID-19 pandemic. J Infect, 2024; 88(1):53–56.
47.
JohnsonSM, McNallyBA, IoannidisI, et al.Respiratory syncytial virus uses CX3CR1 as a receptor on primary human airway epithelial cultures. PLoS Pathog, 2015; 11(12):e1005318.
48.
KenmoeS, NairH. The disease burden of respiratory syncytial virus in older adults. Curr Opin Infect Dis, 2024; 37(2):129–136.
49.
KoivistoK, NieminenT, MejiasA, et al.Respiratory Syncytial Virus (RSV)–Specific antibodies in pregnant women and subsequent risk of RSV hospitalization in young infants. J Infect Dis, 2022; 225(7):1189–1196.
50.
LahamFR, MansbachJM, PiedraPA, et al.Clinical profiles of respiratory syncytial virus subtypes A AND B among children hospitalized with bronchiolitis. Pediatr Infect Dis J, 2017; 36(8):808–810.
51.
LambertL, SagforsAM, OpenshawPJM, et al.Immunity to RSV in early-life. Front Immunol, 2014; 5:466.
52.
LastrucciV, PacificiM, PugliaM, et al.Seasonality and severity of respiratory syncytial virus during the COVID-19 pandemic: A Dynamic Cohort Study. Int J Infect Dis, 2024; 148:107231; doi: 10.1016/j.ijid.2024.107231
53.
LevineS, Klaiber-FrancoR, ParadisoPR. Demonstration that glycoprotein G is the attachment protein of respiratory syncytial virus. J Gen Virol, 1987; 68(9):2521–2524.
54.
LiJ, ChonI, PhyuWW, et al.Molecular epidemiological surveillance of respiratory syncytial virus infection in Myanmar from 2019 to 2023. Sci Rep, 2025; 15(1):13126.
55.
LiY, WangX, BlauDM, et al.; RESCEU investigators. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: A systematic analysis. Lancet, 2022a;399(10340):2047–2064.
56.
LiY, WangX, CongB, et al.Understanding the potential drivers for respiratory syncytial virus rebound during the coronavirus disease 2019 pandemic. J Infect Dis, 2022b;225(6):957–964.
57.
LukensMV, Van De PolAC, CoenjaertsFEJ, et al.A systemic neutrophil response precedes robust CD8+ T-cell activation during natural respiratory syncytial virus infection in infants. J Virol, 2010; 84(5):2374–2383.
58.
MagroM, MasV, ChappellK, et al.Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention. Proc Natl Acad Sci U S A, 2012; 109(8):3089–3094.
59.
MarinND, DunlapMD, KaushalD, et al.Friend or Foe: The protective and pathological roles of inducible bronchus-associated lymphoid tissue in pulmonary diseases. J Immunol, 2019; 202(9):2519–2526.
60.
MartinelloRA, ChenMD, WeibelC, et al.Correlation between respiratory syncytial virus genotype and severity of illness. J Infect Dis, 2002; 186(6):839–842.
61.
McDermottDS, WeissKA, KnudsonCJ, et al.Central role of dendritic cells in shaping the adaptive immune response during respiratory syncytial virus infection. Future Virol, 2011; 6(8):963–973.
62.
McLellanJS. Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein. Curr Opin Virol, 2015; 11:70–75.
63.
MosscropLG, WilliamsTC, TregoningJS. Respiratory syncytial virus after the SARS-CoV-2 pandemic—What next? Nat Rev Immunol, 2022; 22(10):589–590.
64.
MunywokiPK, KoechDC, AgotiCN, et al.The source of respiratory syncytial virus infection in infants: A household cohort study in rural Kenya. J Infect Dis, 2014; 209(11):1685–1692.
65.
NaeimiR, SepidarkishM, MollaloA, et al.SARS-CoV-2 seroprevalence in children worldwide: A systematic review and meta-analysis. EClinicalMedicine, 2023; 56:101786.
66.
NealHE, BarrettCT, EdmondsK, et al.Examination of respiratory syncytial virus fusion protein proteolytic processing and roles of the P27 domain. J Virol, 2024; 98(12):e01639-24.
67.
Nguyen-Van-TamJS, O’LearyM, MartinET, et al.Burden of respiratory syncytial virus infection in older and high-risk adults: A systematic review and meta-analysis of the evidence from developed countries. Eur Respir Rev, 2022; 31(166):220105.
68.
OgilvieMM, VathenenAS, RadfordM, et al.Maternal antibody and respiratory syncytial virus infection in infancy. J Med Virol, 1981; 7(4):263–271.
69.
PapayanniPG, KoukouliasK, KuvalekarM, et al.T cell immune profiling of respiratory syncytial virus for the development of a targeted immunotherapy. Br J Haematol, 2023; 202(4):874–878.
70.
PierangeliA, MidullaF, PirallaA, et al.Sequence analysis of respiratory syncytial virus cases reveals a novel subgroup -B strain circulating in North-Central Italy after Pandemic Restrictions. J Clin Virol, 2024; 173:105681.
71.
PiñanaM, González-SánchezA, AndrésC, et al.Genomic evolution of human respiratory syncytial virus during a decade (2013–2023): Bridging the path to monoclonal antibody surveillance. J Infect, 2024; 88(5):106153.
72.
PletzMW, DürrwaldR, ReicheJ, et al.; CoNAN study group. Impact of the COVID-19 pandemic on influenza and respiratory syncytial virus antibody titres in the community: A Prospective Cohort Study in Neustadt, Thuringia, Germany. Eur Respir J, 2022; 60(5):2200947.
73.
RangaU, AsokanM. Inducing quality immune response to respiratory viruses may not be a simple task. Current Science, 2021; 120(8):1315.
74.
Redlberger‐FritzM, SpringerDN, AberleSW, et al.Respiratory syncytial virus surge in 2022 caused by lineages already present before the COVID‐19 pandemic. J Med Virol, 2023; 95(6):e28830.
75.
ReicherzF, XuRY, Abu-RayaB, et al.Waning immunity against respiratory syncytial virus during the coronavirus disease 2019 pandemic. J Infect Dis, 2022; 226(12):2064–2068.
RiceA, GonzalezG, CarrM, et al.Human respiratory syncytial virus genetic diversity and lineage replacement in Ireland pre- and post-COVID-19 pandemic. Microb Genom, 2025; 11(3):e001379.
78.
Rios-GuzmanE, SimonsLM, DeanTJ, et al.Deviations in RSV epidemiological patterns and population structures in the united states following the COVID-19 pandemic. Nat Commun, 2024; 15(1):3374.
79.
RuckwardtTJ, MorabitoKM, GrahamBS. Determinants of early life immune responses to RSV infection. Curr Opin Virol, 2016; 16:151–157.
80.
RussellCD, UngerSA, WaltonM, et al.The human immune response to respiratory syncytial virus infection. Clin Microbiol Rev, 2017; 30(2):481–502.
81.
SandeCJ, CanePA, NokesDJ. The association between age and the development of respiratory syncytial virus neutralising antibody responses following natural infection in infants. Vaccine, 2014; 32(37):4726–4729.
82.
SandeCJ, MutungaMN, MedleyGF, et al.Group- and genotype-specific neutralizing antibody responses against respiratory syncytial virus in infants and young children with severe pneumonia. J Infect Dis, 2013; 207(3):489–492.
83.
SchmidtME, VargaSM. Modulation of the host immune response by respiratory syncytial virus proteins. J Microbiol, 2017; 55(3):161–171.
84.
SebinaI, PhippsS. The contribution of neutrophils to the pathogenesis of RSV bronchiolitis. Viruses, 2020; 12(8):808.
ShenZ, ZhangY, LiH, et al.Rapid Typing diagnosis and clinical analysis of subtypes A and B of human respiratory syncytial virus in children. Virol J, 2022; 19(1):15.
87.
StaadegaardL, CainiS, WangchukS, et al.Defining the Seasonality of Respiratory Syncytial Virus around the World: National and Subnational Surveillance Data from 12 Countries. Influenza Other Respir Viruses, 2021; 15(6):732–741.
88.
SullenderWM. Respiratory Syncytial Virus Genetic and Antigenic Diversity. Clin Microbiol Rev, 2000; 13(1):1–15, table of contents.
89.
Sutto-OrtizP, EléouëtJ-F, FerronF, et al.Biochemistry of the respiratory syncytial virus l protein embedding RNA polymerase and capping activities. Viruses, 2023; 15(2):341.
90.
TahamtanA, BestemanS, SamadizadehS, et al.Neutrophils in respiratory syncytial virus infection: From harmful effects to therapeutic opportunities. Br J Pharmacol, 2021; 178(3):515–530.
91.
TsutsumiH, MatsudaK, YamazakiH, et al.Different kinetics of antibody responses between IgA and IgG classes in nasopharyngeal secretion in infants and children during primary respiratory syncytial virus infection. Acta Paediatr Jpn, 1995; 37(4):464–468.
92.
WangY, ZhengJ, WangX, et al.Alveolar macrophages and airway hyperresponsiveness associated with respiratory syncytial virus infection. Front Immunol, 2022; 13:1012048.
93.
WeiX, WangL, LiM, et al.Novel imported clades accelerated the RSV surge in Beijing, China, 2023–2024. J Infect, 2024; 89(6):106321.
94.
WeidmannMD, GreenDA, BerryGJ, et al.Assessing respiratory viral exclusion and affinity interactions through co-infection incidence in a pediatric population during the 2022 resurgence of influenza and RSV. Front Cell Infect Microbiol, 2023; 13:1208235.
95.
WelliverTP, GarofaloRP, HosakoteY, et al.Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J Infect Dis, 2007; 195(8):1126–1136.
96.
WestbrookA, WangT, BhaktaK, et al.Respiratory coinfections in children with SARS-CoV-2. Pediatr Infect Dis J, 2023; 42(9):774–780.
97.
WinthropZA, PerezJM, StaffaSJ, et al.Pediatric respiratory syncytial virus hospitalizations and respiratory support after the COVID-19 pandemic. JAMA Netw Open, 2024; 7(6):e2416852.
98.
YuJ-M, FuY-H, PengX-L, et al.Genetic diversity and molecular evolution of human respiratory syncytial virus A and B. Sci Rep, 2021; 11(1):12941.
99.
YunkerM, FallA, NortonJM, et al.Genomic evolution and surveillance of respiratory syncytial virus during the 2023–2024 season. Viruses, 2024; 16(7):1122.
100.
ZhangL, PeeplesME, BoucherRC, et al.Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J Virol, 2002; 76(11):5654–5666.
101.
ZhangY, PuD, LiuQ, et al.Epidemic outbreak of respiratory syncytial virus infection after the end of the Zero‐COVID‐19 Policy in China: Molecular characterization and disease severity associated with a novel RSV‐B clade. J Med Virol, 2025; 97(4):e70343.
102.
ZhivakiD, LemoineS, LimA, et al.Respiratory syncytial virus infects regulatory B cells in human neonates via chemokine receptor CX3CR1 and promotes lung disease severity. Immunity, 2017; 46(2):301–314.
